HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$9.80
-0.07 (-0.71%)
▼
5d:
-1.41%
30d:
-0.2%
90d:
+4.48%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.58
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$8.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $9.80, which is considered fair relative to its 30-day fair value range of $9.51 to $10.06. The stock's valuation (Forward PE: 16.1) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $9.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.75 (+19.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $9.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.75 (+19.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.51 -
$10.06
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($11.75)
Trading Range Analysis
30-Day Trading Range
$9.51 -
$10.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$9.63
Resistance Level
$10.32
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.08
Wall Street Target
$11.75
(+19.9%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
-4.5%
Profit Margin
14.5%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
16.1 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$9.68
(-1%)
2-Year Target
$9.57
(-2%)
3-Year Target
$9.45
(-4%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$9.81
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 7.9%)
$15.85
(+62%)
Base:
(SPY PE: 16.1, Growth: 7.9%)
$12.30
(+26%)
Bear:
(PE: 13.7, Growth: 7.9%)
$10.45
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.56 | Current EPS (TTM): $0.48
Bull Case
$13.78
(+41%)
Analyst growth 27.0%, PE expands to 22.6
Base Case
$12.53
(+28%)
Market implied 27.0%, PE stable at 20.6
Bear Case
$6.71
(-32%)
Severe decline -20.0%, PE contracts to 17.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.1 to 16.7
Stabilization Target:
$10.18
(+3.8%)
PE Expansion Potential:
+3.8%
Share & Embed Analysis
Last updated: August 04, 2026 8:28 AM ET
Data refreshes hourly during market hours. Next update: 9:28 AM
Data refreshes hourly during market hours. Next update: 9:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
